Clinical trials: COVID-19; Immunity
COVID-19
Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management
Persons infected with Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2 vary in severity from being asymptomatic to having fever, cough, sore throat, general weakness and fatigue and muscular pain and in the most severe cases…
- Trial name
- IMMUNOMARKCOV (NCT04668170)
- Testing
- Blood collection on admission and longitudinally, Blood collection on their first consultation and 10 to 14 days later
- Where
- 2 sites in France
- Volunteers
- 304 people
- Sponsor
- University Hospital, Toulouse
Immune Response Post Covid 19 Vaccination
Immune Response of Haemodialysis Patients Post Covid-19 Vaccination
The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination
- Trial name
- Covid-19 (NCT04872751)
- Where
- Malaysia
- Volunteers
- 425 people
- Sponsor
- Penang Hospital, Malaysia
Oncology, COVID-19
Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic
This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19…
- Trial name
- OBVIONCO (NCT04437719)
- Testing
- Obvio-19 app
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
Covid19 Virus Infection
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning.
- Trial name
- COVID (NCT04790240)
- Testing
- Inflammation (I), Inflammation (II), Inflammation (III)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- All Natural Medicine Clinic, LLC
COVID-19, Cancer
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy.
- Trial name
- NCT05313074
- Testing
- CoronaVac vaccine
- Where
- Thailand
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute, Thailand
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2
Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)
Study of the cellular immune response during the SARS-CoV-2 infection and identify cytokinic profiles in caregivers exposed to the virus with asymptomatic forms of COVID19, patients with an asymptomatic form followed in…
- Trial name
- CovImmune (NCT04355351)
- Testing
- blood sampling, additional blood tubes
- Where
- 3 sites in France
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Influenza, Human, SARS-CoV-2 Infection
Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
The objectives of this study are to understand the long-term consequences of repeated annual influenza vaccination among healthcare workers (HCWs) and to use statistical and mathematical modelling to elucidate the immunological…
- Trial name
- NCT05110911
- Testing
- Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad, SARS-CoV-2 vaccination: Comirnaty or Vaxzevria
- Where
- 6 sites in Australia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Dialysis; Complications, COVID-19
Immune Response Following COVID-19 in Hemodialysis Patients
Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19.
- Conditions
- Dialysis; Complications, COVID-19, Cytokine Storm
- Trial name
- IMMUNOVIDIAL (NCT05307601)
- Where
- France
- Volunteers
- 21 people
- Sponsor
- AURA Paris
COVID-19 Vaccination, Inflammation
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity
- Conditions
- COVID-19 Vaccination, Inflammation, Vaccine Immune Response, Vaccine Adverse Reaction
- Trial name
- NCT05315856
- Testing
- either BNT162b2 or ChAdOx1 vaccine
- Where
- 3 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Korea University Guro Hospital
SARS-CoV-2
Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
This is a study of two experimental SARS-CoV-2 vaccines against the virus called SARS-CoV-2 virus. The first of the experimental vaccines is called DoCo-Pro-RBD-1 + M59® and contains a laboratory made protein which looks the same…
- Trial name
- NCT05272605
- Testing
- Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline
- Where
- 2 sites in Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Covid19
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.
- Trial name
- B-EPIC (NCT04796402)
- Testing
- Bamlanivimab, Standard of Care
- Where
- Canada
- Volunteers
- 576 people
- Sponsor
- Fraser Health
Covid19
Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps
This study will evaluate the effectiveness of utilizing Osteopathic Manipulative Treatment (OMT) procedures as an addition to current mRNA COVID-19 vaccines in terms of enhancing the immune response of participants as assessed by…
- Trial name
- NCT04928456
- Testing
- Osteopathic Manipulative Treatment (OMT)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Western University of Health Sciences
COVID-19, Immunity
Study on Immune Status of Patients With COVID-19
This study is a prospective cohort study aimed to clarify the continuous immune state changes of patients with COVID-19. Investigators include the patients admitted to the hospital within one week after the onset of COVID-19.
- Conditions
- COVID-19, Immunity, Life Quality
- Trial name
- NCT05682573
- Testing
- hospitalized patient
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qilu Hospital of Shandong University
Hospital Staff, Vaccined Againt COVID-19
Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff
Vaccination against COVID-19 is a major public health issue to control the epidemic and reduce the number of severe infections and deaths.
- Trial name
- COVIDIM (NCT04896788)
- Testing
- Monitoring of the immune response
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
SARS-CoV-2 Vaccination
Adaptive Immune Response to COVID-19 Vaccination
AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers.
- Trial name
- AICOVI (NCT04826770)
- Testing
- BNT162b2, AZD 1222, mRNA-1273
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
SARS-CoV-2 Infection, Active Immunization
Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately…
- Conditions
- SARS-CoV-2 Infection, Active Immunization, Immune Response, Immunosuppression
- Trial name
- DIA-Vacc (NCT04799808)
- Where
- Germany
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
COVID-19, Cancer
Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients
Evaluation of antibody response against SARS-CoV-2 vaccination in patients treated with IO-treatment, in comparison with antibody titers in patients treated with non-IO treatment.
- Trial name
- VIVACIOUS (NCT05062525)
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- University Health Network, Toronto
Covid-19, SARS-CoV Infection
RT-PCR Database Analysis for COVID-19 Infections and Re-infection
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection.
- Trial name
- ReCOV (NCT04653844)
- Where
- France
- Volunteers
- 7,000,000 people
- Sponsor
- University Hospital, Montpellier